Technologies and Pipeline
PolyImmunex LLC is developing a wide range of technologies including 1) novel adjuvant and adjuvant/vaccine delivery systems, 2) multi-component and multi-functional drug and vaccine delivery systems and 3) innovative vaccine formulations. PolyImmunex's signature products are CINA™ - a new class of synthetic adjuvants and vaccine delivery systems capable of tailored and optimized antigen-specific immune responses
PolyImmunex’s cationic immunostimulatory nanoparticle adjuvant (CINA) platform technology can be utilized with a wide range of existing vaccines and adjuvants to enhance immune responses, safety and length of protection.
PolyImmunex’s CINA technology have been engineered to have the shape and morphology of microbes thereby providing a mechanism by which vaccines engage and harness patients own immune systems for greater responses to vaccines. PolyImmunex's CINA platform technology is capable of co-delivering antigens and adjuvants in the same biodegradable particle directly to professional antigen presenting cells thereby shifting the immune response to the antigen to a therapeutic Th1 bias. The technology is also capable of providing sustained and controlled release of antigens and adjuvants over pre-defined periods of time and providing sequential release of antigens and adjuvants to fine-tune the response further. This technology is based on published peer-reviewed data generated by Prof. Salem and collaborators that are experts in immunology, cancer biology and clinical utility of adjuvants (see scientific advisory board and publications).
PolyImmunex’s proprietary CINA platform can be readily combined with chemotherapeutics such as doxorubicin and is readily adaptable to a wide range of pre-existing antigens and adjuvants.
PolyImmunex’s CINA platform nanoparticle technology have several key unique features:
Tailored antigen-specific immune responses. Published data from the company’s founders have shown that incorporating antigens and adjuvants into the same particle delivery system is able to generate much stronger immune responses than delivery of the same agents in solution. Our CINA platform technology can deliver a wide range of adjuvants and antigens in the same nanoparticle formulation.
Targeted delivery. PolyImmunex’s CINA product platform has been designed to provide targeted delivery to professional antigen presenting cells with reduced uptake by other cell types. This approach allows for dose-sparing and for reduced side-effects.
Prolonged and tailored antigen and adjuvant release. PolyImmunex’s platform CINA technology can be used to provide controlled and tailored release of antigens and adjuvants at desired concentrations over extended periods of time thereby providing a mechanism for longer-term one dose protection.
Programmable sequential release of antigens and adjuvants. PolyImmunex 's CINA platform is the only delivery system capable of providing sequential release of antigens and adjuvants to fine-tune the immune-response and prevent potential adverse formulation problems where the antigen and adjuvant or drug are incompatible
Desirable safety profiles. PolyImmunex’s CINA platform has been developed using materials that have a strong track record of safety in FDA approved products and/or in clinical trials. The main composition of the particle carrier is prepared from a biodegradable polymer that degrades into safe non-toxic clinically acceptable by-products
Platform technology. PolyImmunex’s CINA technology can be utilized with a wide variety of antigens and adjuvants and the final product regardless of antigen or adjuvant is highly amenable to pharmaceutical formulation, scale-up and storage. The technology has shown potential in pre-clinical studies against infectious diseases and a wide range of cancers.
Patent Portfolio
PolyImmunex's intellectual property is based on a broad range of patents issued or pending from the University of Iowa Research Foundation (UIRF) and elsewhere. PolyImmunex LLC continues to build on the intellectual property portfolio with new related disclosures and inventions being developed at the University of Iowa.
PolyImmunex’s cationic immunostimulatory nanoparticle adjuvant (CINA) platform technology can be utilized with a wide range of existing vaccines and adjuvants to enhance immune responses, safety and length of protection.
PolyImmunex’s CINA technology have been engineered to have the shape and morphology of microbes thereby providing a mechanism by which vaccines engage and harness patients own immune systems for greater responses to vaccines. PolyImmunex's CINA platform technology is capable of co-delivering antigens and adjuvants in the same biodegradable particle directly to professional antigen presenting cells thereby shifting the immune response to the antigen to a therapeutic Th1 bias. The technology is also capable of providing sustained and controlled release of antigens and adjuvants over pre-defined periods of time and providing sequential release of antigens and adjuvants to fine-tune the response further. This technology is based on published peer-reviewed data generated by Prof. Salem and collaborators that are experts in immunology, cancer biology and clinical utility of adjuvants (see scientific advisory board and publications).
PolyImmunex’s proprietary CINA platform can be readily combined with chemotherapeutics such as doxorubicin and is readily adaptable to a wide range of pre-existing antigens and adjuvants.
PolyImmunex’s CINA platform nanoparticle technology have several key unique features:
Tailored antigen-specific immune responses. Published data from the company’s founders have shown that incorporating antigens and adjuvants into the same particle delivery system is able to generate much stronger immune responses than delivery of the same agents in solution. Our CINA platform technology can deliver a wide range of adjuvants and antigens in the same nanoparticle formulation.
Targeted delivery. PolyImmunex’s CINA product platform has been designed to provide targeted delivery to professional antigen presenting cells with reduced uptake by other cell types. This approach allows for dose-sparing and for reduced side-effects.
Prolonged and tailored antigen and adjuvant release. PolyImmunex’s platform CINA technology can be used to provide controlled and tailored release of antigens and adjuvants at desired concentrations over extended periods of time thereby providing a mechanism for longer-term one dose protection.
Programmable sequential release of antigens and adjuvants. PolyImmunex 's CINA platform is the only delivery system capable of providing sequential release of antigens and adjuvants to fine-tune the immune-response and prevent potential adverse formulation problems where the antigen and adjuvant or drug are incompatible
Desirable safety profiles. PolyImmunex’s CINA platform has been developed using materials that have a strong track record of safety in FDA approved products and/or in clinical trials. The main composition of the particle carrier is prepared from a biodegradable polymer that degrades into safe non-toxic clinically acceptable by-products
Platform technology. PolyImmunex’s CINA technology can be utilized with a wide variety of antigens and adjuvants and the final product regardless of antigen or adjuvant is highly amenable to pharmaceutical formulation, scale-up and storage. The technology has shown potential in pre-clinical studies against infectious diseases and a wide range of cancers.
Patent Portfolio
PolyImmunex's intellectual property is based on a broad range of patents issued or pending from the University of Iowa Research Foundation (UIRF) and elsewhere. PolyImmunex LLC continues to build on the intellectual property portfolio with new related disclosures and inventions being developed at the University of Iowa.